2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
607
Lung Neoplasms
190
Neoplasms
68
Neoplasm Metastasis
46
Mesothelioma, Malignant
46
Adenocarcinoma of Lung
42
Mesothelioma
40
Colorectal Neoplasms
29
Carcinoma
23
Breast Neoplasms
23
Parkinson Disease 4, Autosomal Dominant Lewy Body
21
Meningeal Carcinomatosis
20
Head and Neck Neoplasms
19
Brain Neoplasms
18
Ovarian Neoplasms
17
Adenocarcinoma
15
Small Cell Lung Carcinoma
14
NSCLC
14
Pancreatic Neoplasms
12
Melanoma
12
Squamous Cell Carcinoma of Head and Neck
11
Recurrence
11
Lung Diseases
10
Carcinoma, Transitional Cell
10
Uterine Cervical Neoplasms
9
Neoplasms by Site
9
Adenocarcinoma, Bronchiolo-Alveolar
9
Thoracic Neoplasms
8
Non-squamous Non-small Cell Lung Cancer
8
Carcinoma, Bronchogenic
8
Interventions
durvalumab
2
tremelimumab
1
ceralasertib
1
aflutinib
1
Radiotherapy
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non Small Cell Lung Cancer NSCLC
×
Pemetrexed
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA